ReviewJournal of gastrointestinal cancer2021
Statins as Potential Therapeutics for Esophageal Cancer.
Review in Journal of gastrointestinal cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- A Systematic Review and Meta-analysis of the Relationship between Statin Intake and Esophageal Cancer.Anti-cancer agents in medicinal chemistry · 2024Pooled it
- PPI Identification of Immune-Related Biomarkers in Esophageal Cancer on the Basis of Gene Co-Expression Network.Iranian journal of biotechnology · 2023Article
- Relation of Statin Use with Esophageal Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Article
- WTAP promotes oesophageal squamous cell carcinoma development by decreasing CPSF4 expression in an mMedical oncology (Northwood, London, England) · 2022Article
- Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer.Pharmaceuticals (Basel, Switzerland) · 2022Review
- miR-18a-5p and ATM Expression in Esophageal Squamous Cell Carcinoma and Their Correlations with Clinicopathological Features.Computational and mathematical methods in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer is a malignancy that has a poor prognosis, which is mainly due to patients presenting once the cancer is in the advances stages. Chemotherapy has been the mainstay for treating esophageal cancer. However, these agents are not consistently effective and fail to differentiate between the different subtypes of esophageal cancers. Targeted therapies have slowly been introduced into the clinical setting, and initial results seem to be promising. Nevertheless, these medications are not universally cheap and also have non-negligible side effects. Therefore, identifying other classes of drugs which could possess anti-esophageal cancer properties is appealing. In addition to expediting the research and development phases of drug discovery, these agents will have known side effect profiles. Statins are a class of cholesterol-lowering medications that have been prescribed for decades. There is a growing body of literature that has shown the anticancer properties of statins in the setting of various malignancies. Herein, we summarize and assimilate the current evidence pertaining to the potential anti-esophageal cancer benefits of statins. We also discuss the limitations of the published studies and consider the future role statins can play in treating patients with esophageal cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.